Disclosure – Non-Independent Marketing Communication
This is a non-independent marketing communication commissioned by International Biotechnology. The report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on the dealing ahead of the dissemination of investment research.
In this episode of Trust Issues, we speak to Ailsa Craig, Investment Manager at International Biotechnology Trust (IBT). The trust recently announced it would be moving to Schroders and we discuss the move, developments in biotech this year, what the IBT managers have been investing in, and more. You can skip to individual questions using the buttons below:
00:00 - Intro and risk warnings
01:17 - What's happening with IBT now you are moving to Schroders?
03:26 - Are we seeing a bounce back in biotech?
09:02 - How are you reinvesting cash from acquisitions?
14:05 - How do you invest for lower volatility but higher returns?
16:45 - Did upping gearing levels work as hoped for?
19:40 - Have rate hikes started to filter out bad companies?
21:13 - Is the trend for new obesity drugs impacting the IBT portfolio and are there other trends investors should be aware of?
22:39 - Should investors be worried about US pricing changes?
Kepler Trust Intelligence provides research and information for professional and private investors. In order to ensure that we provide you with the right kind of content, and to ensure that the content we provide is compliant, you need to tell us what type of investor you are.Read the full article